{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:02:50Z","timestamp":1773745370643,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:00:00Z","timestamp":1545177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s15010-018-1261-y","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T02:03:29Z","timestamp":1545185009000},"page":"289-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime\u2013avibactam"],"prefix":"10.1007","volume":"47","author":[{"given":"Ibai","family":"Los-Arcos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Len","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Mart\u00edn-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Sa\u00e9z-Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Deu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Nuvials","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricard","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Gavald\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,19]]},"reference":[{"key":"1261_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-0034-1396929","volume":"36","author":"IJ Abbott","year":"2015","unstructured":"Abbott IJ, Peleg AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015;36:99\u2013110.","journal-title":"Semin Respir Crit Care Med"},{"key":"1261_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2213-2600(13)70162-0","volume":"2","author":"LJ Lobo","year":"2014","unstructured":"Lobo LJ, Noone PG. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med. 2014;2:73\u201382.","journal-title":"Lancet Respir Med"},{"key":"1261_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","volume":"3","author":"KM Papp-Wallace","year":"2017","unstructured":"Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017;3:502\u201311.","journal-title":"ACS Infect Dis"},{"key":"1261_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","volume":"34","author":"D Weill","year":"2015","unstructured":"Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014\u2014an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1\u201315.","journal-title":"J Heart Lung Transplant"},{"key":"1261_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.healun.2010.06.007","volume":"29","author":"A Soyza De","year":"2010","unstructured":"De Soyza A, Meachery G, Hester KLM, Nicholson A, Parry G, Tocewicz K, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Hear lung Transplant. 2010;29:1395\u2013404.","journal-title":"J Hear lung Transplant"},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D Duin van","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase combinations. Clin Infect Dis. 2016;63:234\u201341.","journal-title":"Clin Infect Dis"},{"key":"1261_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","volume":"46","author":"K Bush","year":"2015","unstructured":"Bush K. A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46:483\u201393.","journal-title":"Int J Antimicrob Agents"},{"key":"1261_CR8","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1128\/JCM.00770-09","volume":"47","author":"T Spilker","year":"2009","unstructured":"Spilker T, Baldwin A, Bumford A, Dowson CG, Mahenthiralingam E, LiPuma JJ. Expanded multilocus sequence typing for Burkholderia species. J Clin Microbiol. 2009;47:2607\u201310.","journal-title":"J Clin Microbiol"},{"key":"1261_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1600-6143.2008.02186.x","volume":"8","author":"BD Alexander","year":"2008","unstructured":"Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, et al. Survival after lung transplantation of cystic Fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025\u201330.","journal-title":"Am J Transplant"},{"key":"1261_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/aje\/153.4.345","volume":"153","author":"TG Liou","year":"2001","unstructured":"Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345\u201352.","journal-title":"Am J Epidemiol"},{"key":"1261_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.transproceed.2017.02.026","volume":"49","author":"M Nosotti","year":"2017","unstructured":"Nosotti M, Dell\u2019Amore A, Diso D, Oggionni T, Aliberti S, Study Group for Thoracic Organs Transplantation E, et al. Selection of candidates for lung transplantation: the First Italian Consensus Statement. Transplant Proc. 2017;49:702\u20136.","journal-title":"Transplant Proc"},{"key":"1261_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/thx.2007.089458","volume":"63","author":"V Boussaud","year":"2008","unstructured":"Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63:732\u20137.","journal-title":"Thorax"},{"key":"1261_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1164\/rccm.200712-1834OC","volume":"178","author":"S Murray","year":"2008","unstructured":"Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363\u201371.","journal-title":"Am J Respir Crit Care Med"},{"key":"1261_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1164\/ajrccm.179.3.257","volume":"179","author":"PM Hopkins","year":"2009","unstructured":"Hopkins PM, Kidd TJ, Coulter C, Feather IH, Derrington P, Bell SC. Death after lung transplantation in cystic fibrosis patients infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2009;179:257\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, et al. Ceftazidime\u2013avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285\u201395.","journal-title":"Lancet Infect Dis"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/jac\/dkv170","volume":"70","author":"DP Nicolau","year":"2015","unstructured":"Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70:2862\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1261_CR17","doi-asserted-by":"publisher","first-page":"e02213-17","DOI":"10.1128\/AAC.02213-17","volume":"62","author":"PD Tamma","year":"2018","unstructured":"Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime\u2013avibactam. Antimicrob Agents Chemother. 2018;62:e02213-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1261_CR18","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/jac\/dky136","volume":"73","author":"G Barlow","year":"2018","unstructured":"Barlow G, Morice A. Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime\/avibactam plus aztreonam. J Antimicrob Chemother. 2018;73:2270\u20131.","journal-title":"J Antimicrob Chemother"},{"key":"1261_CR19","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime\u2013avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615\u20138.","journal-title":"Clin Infect Dis"},{"key":"1261_CR20","first-page":"e02097","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime\u2013avibactam resistance due to plasmid-borne bla KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097\u201316.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-018-1261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-018-1261-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-018-1261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:17:28Z","timestamp":1576714648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-018-1261-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,19]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s15010-018-1261-y","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,19]]},"assertion":[{"value":"26 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"I.L. has been a speaker for Pfizer and has received travel support from Gilead, Merck and Novartis. O.L. has received a research grant from Pfizer and has been speaker for Pfizer, Astellas, Novartis and Merck. The rest of the authors declare that they have no conflicts of interest related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}